Vanta Bioscience Quarterly Results for Trading Insights
In Mar 2023, Vanta Bioscience (VANTABIO) reported revenue ₹1 Cr and net profit ₹-1 Cr — revenue -80.0% YoY. For annual financials, live price and key ratios, visit VANTABIO stock price BSE.
VANTABIO Quarterly Results — Revenue, Profit & EPS Highlights
Vanta Bioscience latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with VANTABIO fundamental valuation to assess whether the stock is under or overvalued.
- Revenue of ₹1 Cr in Mar 2023 (-80.0% vs Mar 2022, -80.0% vs Mar 2022)
- Net Profit of ₹-1 Cr in Mar 2023
- EBITDA of ₹-1 Cr in Mar 2023 (-150.0% vs Mar 2022)
- Operating Margin of -206.0% in Mar 2023 (-252.0pp vs Mar 2022)
Vanta Bioscience Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VANTABIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2023 | Mar 2022 | Dec 2022 | Dec 2021 | QoQ | YoY |
|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1 | 5 | 3 | 0 | -80.0% | -80.0% |
| Net Profit (₹ Cr) | -1 | 0 | -3 | 0 | - | - |
| EBITDA (₹ Cr) | -1 | 2 | -1 | 0 | - | - |
| EPS (₹) | 0.00 | 0.11 | -4.06 | 0.00 | - | - |
| Operating Margin (%) | -206.0% | 46.0% | -20.0% | 0.0% | - | - |
VANTABIO Share Price Trend — 1-Year Movement Across Quarterly Results
Vanta Bioscience 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Vanta Bioscience stock price data download to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VANTABIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vanta Bioscience latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1874.4 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹180,186.80 Cr | 6753.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.6 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹149,924.56 Cr | 4504.4 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 391.3 |
|
Cipla
Mar 2026 |
₹116,150.78 Cr | 1437.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.3 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,873.98 Cr | 1328.4 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 501.3 |
All amounts in ₹ Crores